TG Therapeutics TGTX Reduction Of Lease Liability And Rightofuse Asset Due To Lease Modification

Other financials

Revenue$204.9M+69.6%

Gross profit$171.4M+62.8%

Operating income$34.8M+304%

Net income$19.8M+291%

EPS (diluted)$0.12+300%

Cash & equivalents$442.2M+235%

Total debt$753.6M+197%

Total equity$583.1M+146%

Total assets$1.5B+133%

Operating cash flow-$17.9M+37.7%

CapEx$51.0K+104%

Free cash flow-$17.9M+37.6%

Market cap$8.15B-14.3%

Enterprise value$8.46B-11.1%

P/E17.6×-225×

P/S11.6×-13.0×

Gross margin83.1%-4.4pp

Operating margin21.3%+5.9pp

Net margin66%+55.8pp

FCF margin-6,328.4%+4,773pp

Return on equity112.6%+92.9pp

Debt / equity1.3×+0.2×

Current ratio5.8×+1.8×

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept tgtx:ReductionOfLeaseLiabilityAndRightofuseAssetDueToLeaseModification.

The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is TG Therapeutics's reduction of lease liability and rightofuse asset due to lease modification?: TG Therapeutics (TGTX) reported reduction of lease liability and rightofuse asset due to lease modification of $1.13M in Q1 2026.